In a report issued on August 13, Scott Henry from Roth Capital reiterated a Buy rating on BioDelivery (NASDAQ: BDSI), with a price target of $4.50. The company’s shares opened today at $2.65.
According to TipRanks.com, Henry is a 4-star analyst with an average return of 3.8% and a 44.5% success rate. Henry covers the Healthcare sector, focusing on stocks such as Titan Pharmaceuticals, Viking Therapeutics, and Lemaitre Vascular.
BioDelivery has an analyst consensus of Moderate Buy, with a price target consensus of $4.25, representing a 60.4% upside. In a report issued on August 9, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $4.50 price target.
.
See today’s analyst top recommended stocks >>
Based on BioDelivery’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.77 million. In comparison, last year the company had a GAAP net loss of $14.88 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioDelivery Sciences International, Inc. is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction.
